Drug Trial Radar · NCT06840496
To Investigate the Efficacy of Treatment With Oral NA-921 (Bionetide) Versus Placebo in Females With Rett Syndrome
Last checked: Nov 19, 2026Latest source record: Mar 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
210
Planned (sponsor's estimate)
Start
Sep 30, 2026
Primary completion
Sep 30, 2027
Study completion Dec 30, 2027
Sponsor
- Lead sponsor
- Biomed Industries, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Bioneurals Ltd
- First posted
- Feb 21, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 5 years, up to 20 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Primary Objective • To investigate the efficacy of treatment with oral Bionetide versus placebo in girls and women with Rett syndrome Key Secondary Objective • To investigate the efficacy of treatment with oral Bionetide versus placebo on ability to communicate in girls and women with Rett syndrome
Conditions
- Rett Syndrome
Interventions
BionetideDrug
Bionetide solution of 20-40 mL based on the subject's weight at Baseline, administered twice daily by mouth or gastrostomy tube (G-tube)
PlaceboDrug
Placebo • Bionetide placebo solution administered based on the subject's weight at Baseline, twice daily for 12 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Rett Syndrome Behavior Questionnaire (RSBQ) Total Score - Change From Baseline to Week 12Time frame: Baseline and Week 12
- Clinical Global Impression-Improvement (CGI-I) Score at Week 12Time frame: 12 Weeks Treatment Duration
Locations
18 sites in 2 countries. Site status is shown where the registry gives one.
Biomed Testing Facility # BIO-01-85012
Phoenix, Arizona · Recruiting
Biomed Testing Facility # BIO-05-92093
La Jolla, California · Recruiting
Biomed Testing Facility # BIO-04-90095
Los Angeles, California · Recruiting
Biomed Testing Facility # BIO-03-95817
Sacramento, California · Recruiting
Biomed Testing Facility # BIO-02-94104
San Francisco, California · Recruiting
Biomed Testing Facility #BIO-06-80042
Aurora, Colorado · Recruiting
Biomed Testing Facility #BIO-07-33606
Tampa, Florida · Recruiting
Biomed Testing Facility #BIO-08-60612
Chicago, Illinois · Recruiting
Maryland Locations Biomed Testing Facility #BIO-9-21205
Baltimore, Maryland · Recruiting
Biomed Testing Facility #BIO-10-02115
Boston, Massachusetts · Recruiting
Biomed Testing Facility #BIO-13-10467
The Bronx, New York · Recruiting
Biomed Testing Facility #BIO-17-19104
Philadelphia, Pennsylvania · Recruiting
Biomed Testing Facility #BIO-19-77030
Houston, Texas · Recruiting
Biomed Testing Facility #BIO-20-98105
Seattle, Washington · Recruiting
Biomed Research Unit-BIO-23-NSW 2050
Camperdown, New South Wales, Australia · Recruiting
Biomed Research Unit-BIO-24-NSW-4101
South Brisbane, Queensland, Australia · Recruiting
Biomed Research Unit-BIO-21-VIC-3084
Heidelberg West, Victoria, Australia · Recruiting
Biomed Research Unit- BIO-22-VIC 3010
Parkville, Victoria, Australia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.